leukemias and multiple myeloma,” said Michael Ports, Chief Scientific Officer of CARGO Therapeutics. “Knowledge is increasing about mechanisms that contribute to poor outcomes to cell therapy. At CARGO, we apply this know...
Expanding the payload capacity of transposons could facilitate more sophisticated cargo designs, improving the regulation of expression and minimizing mutagenic risks associated with molecular therapeutics, metabolic engineering, and transgenic animal production. In this study, we improved the Tol2 transposon ...
et al. Alzheimer’s therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS ONE 9, e111899 (2014). Article ADS PubMed PubMed Central CAS Google Scholar Ahmed, I. S., Rohe, H. J., Twist, K. E. ...